[Clinical value of microchip technology in determination of drug resistance of Mycobacterium tuberculosis]

Probl Tuberk. 2002:(6):21-4.
[Article in Russian]

Abstract

The patients with multiresistant tuberculosis were divided into 2 groups: the sensitivity of Mycobacteria tuberculosis to antituberculous drugs was evaluated in Group 1 by the methods of absolute concentrations and in Group 2 by biological microchips determining mutations in the rpo3 gene responsible for rifampicin resistance. The results of the drug sensitivity test were obtained after 3 months of treatment in Group 1 and several days prior treatment in Group 2. By taking into account the test results, reserve drugs was used in Group 2 patients. Subsequently, the results of the drug sensitivity tests carried out by the bacteriological method in Group 2 patients showed that isoniazid resistance was simultaneously noted if there were mutations in the rpo-B gene. Timely treatment with reserve drugs exhibited higher efficiency of treatment with its shorter duration in Group 2 than in Group 1.

Publication types

  • Comparative Study
  • English Abstract

MeSH terms

  • Adult
  • Antibiotics, Antitubercular / pharmacology*
  • Antibiotics, Antitubercular / therapeutic use
  • Antitubercular Agents / pharmacology*
  • Antitubercular Agents / therapeutic use
  • Drug Resistance, Multiple, Bacterial / genetics*
  • Female
  • Humans
  • Isoniazid / pharmacology
  • Isoniazid / therapeutic use
  • Male
  • Microbial Sensitivity Tests
  • Mutation
  • Mycobacterium tuberculosis / drug effects*
  • Mycobacterium tuberculosis / genetics*
  • Rifampin / pharmacology
  • Rifampin / therapeutic use
  • Tuberculosis, Multidrug-Resistant / drug therapy*
  • Tuberculosis, Multidrug-Resistant / genetics

Substances

  • Antibiotics, Antitubercular
  • Antitubercular Agents
  • Isoniazid
  • Rifampin